Big Pharma Split Corp.
TSX:PRM.TO
11.2 (CAD) • At close July 4, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CAD.
| 2024 Q4 | 2024 Q2 | 2023 Q4 | 2023 Q2 | 2022 Q4 | 2022 Q2 | 2021 Q4 | 2021 Q2 | 2020 Q4 | 2020 Q2 | 2019 Q4 | 2019 Q2 | 2018 Q4 | 2018 Q2 | 2017 Q4 | 2017 Q2 | 2016 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.736 | 1.113 | 0.719 | -0.398 | 3.027 | 3.601 | 3.071 | 2.491 | -0.092 | 0.802 | 3.515 | -1.116 | 4.299 | 2.088 | 0.808 | 0.204 | 0.102 |
| Cost of Revenue
| 0.154 | 0.162 | 0 | 0 | 0.217 | 0 | 0 | 0 | 0 | 0 | 0 | 0.119 | 0.119 | 0.137 | 0.069 | 0 | 0 |
| Gross Profit
| 0.582 | 0.951 | 0.719 | -0.398 | 2.81 | 3.601 | 3.071 | 2.491 | -0.092 | 0.802 | 3.515 | -1.236 | 4.179 | 1.95 | 0.739 | 0.204 | 0.102 |
| Gross Profit Ratio
| 0.791 | 0.854 | 1 | 1 | 0.928 | 1 | 1 | 1 | 1 | 1 | 1 | 1.107 | 0.972 | 0.934 | 0.915 | 1 | 1 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 0 | 0.303 | 0.276 | 0.192 | 0.306 | 0.43 | 0.403 | 0.183 | 0.245 | 0.252 | 0.273 | 0.297 | 0.31 | 0.08 | 0.039 | 0.019 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.055 | 0.055 | -0.094 | -0.047 | -0.036 | -0.018 |
| SG&A
| 4.141 | -1.102 | 0.303 | 0.276 | 0.192 | 0.306 | 0.43 | 0.403 | 0.183 | 0.245 | 0.252 | 0.273 | 0.297 | 0.31 | 0.033 | 0.003 | 0.002 |
| Other Expenses
| -2.071 | 0.551 | 0 | 0 | -2.098 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 2.071 | -0.551 | 0.54 | 0.079 | 2.098 | 1.167 | 1.124 | 0.46 | 1.118 | 1.563 | 0.087 | 0.833 | 1.717 | 1.889 | 0.033 | 0.003 | 0.002 |
| Operating Income
| -1.489 | 1.502 | 0.37 | -0.733 | 0.711 | 3.149 | 2.589 | 2.017 | -0.315 | 0.502 | 3.225 | -1.461 | 3.955 | 1.705 | 1.487 | 0.162 | 0.081 |
| Operating Income Ratio
| -2.024 | 1.349 | 0.514 | 1.839 | 0.235 | 0.875 | 0.843 | 0.81 | 3.413 | 0.625 | 0.917 | 1.308 | 0.92 | 0.816 | 1.841 | 0.794 | 0.794 |
| Total Other Income Expenses Net
| -0.289 | -0.263 | -0.448 | 0.166 | -0.976 | -1.09 | -1 | 3.225 | 1.108 | -2.521 | -0.061 | 0.877 | -1.709 | -1.846 | -0.792 | 0 | 0 |
| Income Before Tax
| -1.778 | 1.24 | -0.078 | -0.567 | 0.33 | 2.059 | 1.589 | 2.621 | 0.792 | -1.01 | 3.164 | -0.584 | 2.246 | -0.142 | 0.695 | 0.162 | 0.081 |
| Income Before Tax Ratio
| -2.417 | 1.113 | -0.109 | 1.424 | 0.109 | 0.572 | 0.517 | 1.052 | -8.573 | -1.258 | 0.9 | 0.523 | 0.523 | -0.068 | 0.86 | 0.794 | 0.794 |
| Income Tax Expense
| 0 | 0 | -0.448 | 0.166 | -1.141 | -1.09 | -1 | 0.604 | 1.108 | -1.511 | -0.061 | -0.672 | -0.672 | 1.584 | 0.792 | 0 | 0 |
| Net Income
| -1.778 | 1.24 | -0.078 | -0.567 | 0.33 | 2.059 | 1.589 | 2.621 | 0.792 | -1.01 | 3.164 | -0.584 | 2.246 | -0.142 | -0.097 | 0.162 | 0.081 |
| Net Income Ratio
| -2.417 | 1.113 | -0.109 | 1.424 | 0.109 | 0.572 | 0.517 | 1.052 | -8.573 | -1.258 | 0.9 | 0.523 | 0.523 | -0.068 | -0.12 | 0.794 | 0.794 |
| EPS
| -1.54 | 0.99 | -0.066 | -0.46 | 0.26 | 1.36 | 1.14 | 2.2 | 0.84 | -0.96 | 3 | -0.44 | 1.66 | -0.104 | -0.072 | 0.119 | 0.059 |
| EPS Diluted
| -1.54 | 0.99 | -0.066 | -0.46 | 0.26 | 1.36 | 1.14 | 2.2 | 0.84 | -0.96 | 3 | -0.44 | 1.66 | -0.104 | -0.072 | 0.119 | 0.059 |
| EBITDA
| -1.485 | 1.506 | -0.448 | 0.166 | 0.711 | -1.09 | -1 | 0.604 | 2.052 | -2.019 | -0.061 | 0.877 | -1.709 | -1.846 | 0.695 | 0.162 | 0.081 |
| EBITDA Ratio
| -2.018 | 1.353 | -0.622 | -0.415 | 0.235 | -0.303 | -0.326 | 0.242 | -22.204 | -2.517 | -0.017 | -0.786 | -0.397 | -0.884 | 0.86 | 0.794 | 0.794 |